

Fourth Quarter and Full-Year 2020 Financial Results and Business Updates

April 15, 2021

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Franz-Werner Haas

Business Update

Chief Executive Officer

Ulrike Gnad-Vogt

Clinical Update

Interim Chief Development Officer

Pierre Kemula

Financial Update

Chief Financial Officer

Mariola Fotin-Mleczek

Q&A Availability

Chief Technology Officer





Clinical Developments

CVnCoV: COVID-19 vaccine candidate

- Pivotal Phase 2b/3:
 - Fully recruited with over 40,000 participants
 - Amendment submitted to address virus variants
 - Interim analysis for vaccine efficacy exp. Q2 2021
- Phase 2a amendment for vaccine efficacy submitted
- Expanding COVID-19 vaccine program:
 - Three new Phase 3 trials to be initiated shortly
 - Phase 2a expansion for adolescents
- CVnCoV protection demonstrated against South African variant in preclinical challenge study

CV8102: Cancer immuno-modulator in solid tumors

- Phase 1 expansion cohort initiated in advanced melanoma
- Preferred dose of 600µg selected for anticipated Phase 2



COVID-19 Program Partnerships

- Bayer collaboration: 1st generation COVID-19 vaccines
- GSK collaboration: 2nd generation COVID-19 vaccines
- UK Government: variant expertise and scientific input*



CVnCoV Manufacturing

- Adding partners for broad manufacturing network
- Increasing 2022 capacity guidance to up to 1bn
- Reaffirming 2021 capacity guidance of up to 300m




Financial results

- Capital raise: gross proceeds of \$517.5 million
- Cash position of €1.32 billion as of Dec 31st, 2020

2020 – Year of Corporate Transformation



2020 – Propelling CureVac Forward



*The forecast is prepared by the Company's management using its best estimate and judgment based on past experience and actual knowledge and progress of the Company's performance as of the date of this presentation, and have been based on several assumptions, many of which are outside the influence of the Company's management. Any deviation of certain of these assumptions could materially change the outcome of the forecast.

Our Core Mandate 2021: Deliver a Safe and Effective COVID-19 Vaccine

Succeeding in the clinic

- Expect to provide first efficacy data in Q2 2021
- Expect to apply for regulatory approval in Q2 2021

Creating capacity


- 3 in-house GMP certified suites
- 4th large-scale suite in progress
- Broad and integrated European CDMO network

Delivering the vaccine

- Bayer adding key operational and commercial support
- GSK adding expertise for joint development of 2nd-generation COVID-19 vaccines







CureVac Pipeline: A Diversified Portfolio




(1) We have initiated a combined Phase 2b/3 clinical trial for CVnCoV (2) CEPI early stage Phase 1 clinical trial funding
 cMEL: Cutaneous melanoma; ACC: Adenoid cystic carcinoma; SCC: Squamous cell carcinoma; HNSCC: Squamous cell carcinoma of head and neck | 8

Rapidly Expanding the COVID-19 Vaccine Program

COVID-19 Program: CVnCoV

TRIAL NO.	CLINICAL STUDY	LOCATION	OBJECTIVE	STUDY SIZE	STATUS	DOSE	EXP. DATA
004 (HERALD)	Phase 2b/3	Europe Latin America	Safety and efficacy	>40,000	Fully recruited	12 µg	Q2/2021
005	Phase 3	Germany (Mainz)	Healthcare population	2,500	>90% recruited	12 µg	Q2/2021
002	Phase 2a	Peru Panama	Dose- confirmation	674	Fully recruited	6µg / 12 µg	Q2/2021
001	Phase 1	Germany Belgium	Dose- escalation	280	Fully recruited	2-20 µg	Publication submitted
002	Phase 2a amendment 	Peru	Adolescents (12 to 17)	40 (initial cohort)	Amendment submitted	6 µg / 12 µg	
003	Phase 3 	Belgium	Participants with co-morbidities	1,200	Starting shortly	12 µg	
011	Phase 3 	Argentina, Colombia, Peru	Co-administration with flu vaccine	1,000	Starting shortly	12 µg	
012	Phase 2 	France	Age comparison (18-45 vs. ≥65)	180	Starting shortly	12 µg	
	UK Government Vaccine Task Force*	-	CVnCoV variant optimized	-	Expected start in Q3/2021	-	-
	GSK partnership	-	2 nd generation COVID-19 vaccine	-	Expected start in Q3/2021	-	-

Variants of Concern Spreading in Phase 2b/3 Trial Geographies



Adjusting Late-Stage CVnCoV Trials to the Dynamics of the Virus

PHASE 2b/3

- Fully enrolled
- Over 40,000 participants
- 1:1 randomization

ADDRESSING VARIANTS OF CONCERN

- Secondary endpoint added addressing variants
- Specifying variant-dependent efficacy readout
- Original and UK strain for additional analysis

PHASE 2a

- Fully enrolled
- ~270 participants aged over 60 vaccinated
- 10:1 randomization

UTILIZING HIGH COVID-19 PREVALENCE

- Harness potential of high COVID-19 case numbers
- Include secondary endpoint for efficacy
- Data focus on important group of older adults

Evidence of Protection Against South Africa Strain in Preclinical Study



Variant of Concern
B.1.351 (SA strain)

Original strain
BavPat1

Efficient protection from **challenge with B.1.351** by vaccination with 8µg of CVnCoV

CENTRAL NERVOUS SYSTEM:
BRAIN

- **Full protection,**
no B.1.351 detectable

UPPER RESPIRATORY TRACT:
CONCHAE

- **Residual viral load**
no statistical significance

LOWER RESPIRATORY TRACT:
TRACHEA, LUNGS

- **Full protection,**
no B.1.351 detectable



Survival non-vaccinated		Survival CVnCoV vaccinated	
BavPat1	20%	BavPat1	100%
B.1.351	0%	B.1.351	100%

- Vaccinated animals were protected from **disease and mortality**
- Robust induction of antibody titers for BavPat1, **significantly lower** antibody titers for B.1.351

Expanding European Manufacturing Network with Experienced Partners

Manufacturing partners




2021



Up to 300 million doses

2022



Up to 1 billion doses



mRNA
production



mRNA
formulation



Fill & Finish



Packaging

The RNA Printer[®], Decentralized Mobile mRNA Production



RNA Printer[®] 2.0



pDNA
production




mRNA
production

PANDEMIC PREPAREDNESS
in hospitals in outbreak regions


CUSTOMIZED, POINT OF CARE
mRNA vaccines and therapeutics

CLINICAL DEVELOPMENT
acceleration at lower costs


Solid Foundation for Sustainable Value Creation



Capital Inflow Fuels Corporate Transformation



Follow-On Financing: Securing Additional Funds to Grow the Business







Cash and Condensed Consolidated P&L Statement

	Year ended December 31,	
(in € millions)	2020	2019
	unaudited	
Cash and Cash Equivalents	1,322.6	30.7

	Year ended December 31,	
(in € millions)	2020	2019
	unaudited	
Revenue	48.9	17.4
Operating Expenses	-158.7	-116.9
Operating Result	-109.8	-99.5
Financial Result	-20.0	-0.6
Earnings before Taxes (EBT)	-129.8	-100.1

	Three Month ended December 31,	
	2020	2019
	unaudited	
	6.0	6.8
	-52.6	-41.9
	-46.6	-35.1
	-10.7	-0.8
	-57.3	-35.9

Summary and Highlights

-  A year of fundamental corporate transformation further advances development from Biotech to a commercial Biopharma company
-  CureVac's COVID-19 lead candidate, CVnCoV, in final stage of clinical development and well on track for conditional approval
-  Positioned for sustained value creation in the pandemic and beyond with strong partners, first- and second-generation vaccines and oncology pipeline
-  Expanding European manufacturing network with highly experienced partners for capacity ramp-up and updated 2022 guidance
-  Nasdaq listing and favorable cash position of €1.32 billion*





**Thank you for your
attention**

CureVac
www.curevac.com